Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy

February 19, 2009
Publication
Article
OncologyONCOLOGY Vol 23 No 2
Volume 23
Issue 2

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

The study looked at 396 women who were treated with a mastectomy for breast cancer. The researchers found that 19% of women who fell clearly within guidelines recommending radiation after the mastectomy did not receive that treatment. Results of the study appear online in the journal Cancer and will be published in the March 15 issue.

Postmastectomy radiation is known to decrease the risk of cancer returning in the chest wall and has been shown to reduce mortality in high-risk patients, but there has been some debate within the cancer community about who is likely to benefit most. Current guidelines recommend radiation after mastectomy for women who had particularly large tumors or cancer in four or more of their nearby lymph nodes. Even women with fewer positive lymph nodes should strongly consider radiation treatment.

Potentially Lifesaving Treatment
“There’s an identifiable high-risk group for whom there’s absolutely no debate-they need radiation after their mastectomy. Even in this group for whom it’s crystal clear, we found that only four-fifths were treated. That’s not good enough. This is a potentially lifesaving treatment,” says lead study author Reshma Jagsi, MD, DPhil, assistant professor of radiation oncology at the U-M Medical School.

The most common reason women cited for not considering radiation therapy was that their doctors did not recommend it. “Much attention has been focused on educating people that they need radiation after lumpectomy. But many women assume having a mastectomy means radiation won’t be needed. That’s not always the case, and patients choosing one surgery over another hoping to avoid radiation need to be aware of this,” Jagsi says.

Articles in this issue

Adjuvant Therapy for Colorectal Cancer: Increasingly Complex as Patients Age
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
The Growing Importance of Skin Toxicity in EGFR Inhibitor Therapy
In Search of Rigorous Data on How to Palliate the EGFR Inhibitor–Induced Rash
Endocrine Therapy in 2009: Consideration of the Tumor and the Host
Predicting Endocrine Responsiveness: Novel Biomarkers on the Horizon
Adjuvant Chemotherapy for Colon Cancer in the Elderly: Moving From Evidence to Practice
How Should We Care for Elderly Cancer Patients?
Acai Berry
Acai Berry
Predicting Endocrine Therapy Responsiveness in Breast Cancer
Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Advertisement

The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Andrea I. Nañez, MD;Maria A. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS
December 4th 2025
Article


AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies

Ram Prakash Thirugnanasambandam, MBBS;Ariana Bauer, MD;Christopher D’Angelo, MD
December 3rd 2025
Article

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

Related Content
Advertisement

The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Andrea I. Nañez, MD;Maria A. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS
December 4th 2025
Article


AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies

Ram Prakash Thirugnanasambandam, MBBS;Ariana Bauer, MD;Christopher D’Angelo, MD
December 3rd 2025
Article

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.